How are you taking part in this consultation?

You will not be able to change how you comment later.

You must be signed in to answer questions

  • Question on Consultation

    Has all of the relevant evidence been taken into account?

  • Question on Consultation

    Are the summaries of clinical and and cost effectiveness reasonable interpretations of the evidence?

  • Question on Consultation

    Are the recommendations sound and a suitable basis for guidance to the NHS?

  • Question on Consultation

    Are there any aspects of the recommendations that need particular consideration to ensure we avoid unlawful discrimination against any group of people on the grounds of race, sex, disability, religion or belief, sexual orientation, age, gender reassignment, pregnancy and maternity?
The content on this page is not current guidance and is only for the purposes of the consultation process.

Tafasitamab with lenalidomide for treating relapsed or refractory diffuse large B‑cell lymphoma

Closed for comments This consultation ended on at   Request commenting lead permission

1 Recommendations

1.1 Tafasitamab with lenalidomide is not recommended, within its marketing authorisation, for treating relapsed or refractory diffuse large B-cell lymphoma in adults who cannot have an autologous stem cell transplant.

1.2 This recommendation is not intended to affect treatment with tafasitamab with lenalidomide that was started in the NHS before this guidance was published. People having treatment outside this recommendation may continue without change to the funding arrangements in place for them before this guidance was published, until they and their NHS clinician consider it appropriate to stop.

Why the committee made these recommendations

People with relapsed or refractory diffuse large B-cell lymphoma who cannot have an autologous stem cell transplant usually have polatuzumab vedotin with rituximab and bendamustine.

The clinical evidence is from a small study that did not directly compare tafasitamab plus lenalidomide with anything else. The committee considered that the study results were promising because they show that some people's disease responds to tafasitamab plus lenalidomide. Indirect evidence suggests people who have tafasitamab plus lenalidomide have more time before their disease gets worse than people who have polatuzumab vedotin plus rituximab and bendamustine. It also suggests that they live longer. But there is uncertainty about these results because the survival times for people who have polatuzumab vedotin plus rituximab and bendamustine used in the modelling does not reflect the estimated survival in NICE's guidance on polatuzumab vedotin plus rituximab and bendamustine. The methods used for the indirect comparisons are also not clear.

People on standard treatment for relapsed or refractory diffuse large B-cell lymphoma are likely to live for longer than 2 years so do not meet one of NICE's criteria for end of life.

All the cost-effectiveness estimates for tafasitamab plus lenalidomide are above the range normally considered by NICE to be a cost-effective use of NHS resources. Therefore, it cannot be recommended for routine use in the NHS.

Because the cost-effectiveness estimates are very high and uncertain, and further evidence is unlikely to resolve this uncertainty, it also cannot be recommended for use in the Cancer Drugs Fund.